Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Obesity 5Polycystic Ovary Syndrome 4Prostatic Neoplasms 2Pancreatic Neoplasms 1Overweight 1Neoplasms 1Metabolic Syndrome 1Inflammation 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Dyslipidemias 1Diabetes Mellitus, Type 2 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

relacorilant 5Pioglitazone 4Metformin 4Sitagliptin Phosphate 3Resistance Training 3Dipeptidyl-Peptidase IV Inhibitors 3saxagliptin 2Vildagliptin 2Sulfonylurea Compounds 2Rosiglitazone 2Nutritional Status 2Blood Specimen Collection 2voglibose 1somapacitan 1semaglutide 1repaglinide 1pembrolizumab 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1dapagliflozin 1alogliptin 1Urine Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Type 2 × semaglutide × Clear all
NCT04572165 2024-01-02

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Novo Nordisk A/S

Unknown
600,000 enrolled

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡